An experimental drug set to change the landscape of pancreatic cancer treatment has officially just become medical reality.
On Wednesday, the Food and Drug Administration approved Revolution Medicines’ daraxonrasib as a last resort option for adults with metastatic pancreatic adenocarcinoma (PDAC). In late-stage clinical trials, the drug doubled people’s length of survival compared to standard chemotherapy. Daraxonrasib, which will be sold under the brand name Rasonque, is poised to be the first in a new class of medications that can attack a long-elusive target commonly found in pancreatic and other cancers.
“Today’s approval provides a…
Read the full article at GIZMODO.COM
